Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHD), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharma (HOPHD) is a clinical-stage biopharmaceutical company pioneering novel therapies for blood disorders and autoimmune diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's scientific advancements and operational developments.
Access authoritative information about clinical trial progress, regulatory milestones, and strategic partnerships in one centralized location. Our curated collection includes press releases covering drug development breakthroughs, research collaborations, and technology innovations from Hemogenyx Pharma's proprietary platform.
Stay informed about critical updates including FDA communications, trial phase transitions, and intellectual property developments. All content is verified for accuracy and relevance to support informed decision-making. Bookmark this page for direct access to essential updates about HOPHD's therapeutic pipeline and corporate announcements.
Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £340,000 through a placing of 100,000 new ordinary shares at 340p per share. The institutional investor participating in the placing has also received 50,000 warrants, exercisable at 500p each from March 1, 2025, for a 12-month period.
The proceeds will fund the clinical trial of HG-CT-1, the company's lead asset targeting relapsed/refractory acute myeloid leukemia (AML) in adults. The first patient is currently being evaluated for trial inclusion. Trading of the new shares on the London Stock Exchange's Main Market is expected around January 15, 2025.
Following the admission, the company's enlarged issued share capital will comprise 3,604,539 ordinary shares, with no shares held in treasury. The new shares will rank equally with existing ordinary shares.
